Abstract
Patients are considered to be at high risk of cardiovascular events if they have diabetes, chronic kidney disease, stroke, established coronary artery disease, or a coronary artery disease equivalent. Blood pressure-lowering therapy has been shown to reduce cardiovascular events in these patients significantly. Identification of high-risk patients by global risk evaluation is recommended for every hypertensive patient. Treatment of hypertension in high-risk patients with an angiotensin-converting enzyme inhibitor or an angiotensin receptor antagonist, with or without addition of a dihydropyridine calcium channel antagonist, is a reasonable approach based on current clinical trials.
Original language | English |
---|---|
Pages (from-to) | 137-141 |
Number of pages | 5 |
Journal | Vascular Health and Risk Management |
Volume | 7 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2011 |
All Science Journal Classification (ASJC) codes
- Endocrinology, Diabetes and Metabolism
- Hematology
- Public Health, Environmental and Occupational Health
- Cardiology and Cardiovascular Medicine
- Pharmacology (medical)